Advertisement
New Zealand markets close in 3 hours 32 minutes

  • NZX 50

    11,876.56
    -69.87 (-0.58%)
     

  • NZD/USD

    0.5965
    +0.0016 (+0.26%)
     

  • NZD/EUR

    0.5558
    +0.0018 (+0.33%)
     

  • ALL ORDS

    7,848.50
    -89.00 (-1.12%)
     

  • ASX 200

    7,588.30
    -94.70 (-1.23%)
     

  • OIL

    83.83
    +0.26 (+0.31%)
     

  • GOLD

    2,339.80
    -2.70 (-0.12%)
     

  • NASDAQ

    17,430.50
    -96.30 (-0.55%)
     

  • FTSE

    8,078.86
    +38.48 (+0.48%)
     

  • Dow Jones

    38,085.80
    -375.12 (-0.98%)
     

  • DAX

    17,917.28
    -171.42 (-0.95%)
     

  • Hang Seng

    17,284.54
    0.00 (0.00%)
     

  • NIKKEI 225

    37,630.23
    +1.75 (+0.00%)
     

  • NZD/JPY

    92.7830
    +0.2870 (+0.31%)
     

Why Biohaven Stock Caught Fire This Week

George Budwell, The Motley Fool
·2-min read
Why Biohaven Stock Caught Fire This Week

Shares of the clinical-stage biopharma Biohaven (NYSE: BHVN) rocketed higher by 33.5% over the first four days of trading this week, according to data provided by S&P Global Market Intelligence. The big gain was sparked by the company's research and development day presentation held on Wednesday. Highlights from Biohaven's presentation include the unexpected Food and Drug Administration (FDA) regulatory filing for the experimental spinocerebellar ataxia type 3 drug troriluzole, status updates on its closely watched epilepsy program, and a clinical strategy overview for its newly acquired neuroinflammatory asset BHV-8000.

Continue reading